Allison Berger
Allison Berger has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Christopher C. DuFort
Presage Biosciences, Seattle, Washington
188 shared publications - Claire Williams
Department of Biology, University of Washington
188 shared publications - Connor Burns
Presage Biosciences, Seattle, WA
188 shared publications - Daniel Clayburgh
Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon
188 shared publications - Dennis Huszar
Takeda Development Center Americas, Inc., Boston, Massachusetts
188 shared publications - Emily Beirne
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington
188 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment
Table S2 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment
Table S2 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment
- Open Access
- 31 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Preclinical efficacy study (groups)
- 31 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Preclinical efficacy study (groups)